Renovion is a pre-clinical stage pharmaceutical company with a therapy for chronic inflammatory airway diseases. Our goal is to be the first drug ever approved for patients that have received a bilateral lung transplant. After success in these patients, we want to help patients in other areas such as cystic fibrosis, asthma and chronic obstructive pulmonary disease (COPD).
Meet the dynamic team passionate about making Renovion a success
Aiming to be the first FDA Approved therapy for lung transplant patients
Investor documentation and reports available upon request